


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-5.65%
+0.64%
+3.34%
+0.45%
PHGE
BiomX
$0.26
Strengths

Earnings are forecast to grow
Chart
$0.54 (-51.85%)
$0.53 (-50.94%)
$0.44 (-40.91%)
$0.6 (-56.67%)
PHGE has Extreme risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Price under $5

High volatilty

PHGE overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
PHGE Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
PHGE Street Sentiment is unimpressive and have negative views on the near-term outlook
What is PHGE current stock price?
What are PHGE stock strengths?
What is PHGE Risk Level?
What is PHGE market cap and volume?
What is PHGE current Stock IQ?
Should I buy PHGE stock right now?
Is PHGE a Strong Buy right now?
What does a 'Strong Buy' rating mean for PHGE?
What does a 'Strong Sell' rating mean for PHGE?
What factors influence PHGE's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-5.65%
+0.64%
+3.34%
+0.45%
PHGE
BiomX
Current Price
$0.26
Stock Insights
Strengths

Earnings are forecast to grow

Chart
$0.54 (-51.85%)
$0.53 (-50.94%)
$0.44 (-40.91%)
$0.6 (-56.67%)
PHGE Analysts Opinion
PHGE Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
PHGE Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
PHGE Street Sentiment is unimpressive and have negative views on the near-term outlook
PHGE has Extreme risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Price under $5

High volatilty

PHGE Latest Analysis
BiomX announces 1-for-19 reverse stock split.
Fri Nov 14, 2025
BiomX Inc. Announces 1-for-19 Reverse Stock Split. NESS ZIONA Israel Nov. 14 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (BiomX or the Company) a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria today announced that it intends to effect a one-for-nineteen reverse split (the Reverse Stock Split) of the Companys common stock (the Common Stock). The Common Stock will continue to trade on the NYSE American under the ex
Fri Nov 14, 2025
BiomX Inc. (AMEX:PHGE) Q3 2025 Earnings Call Transcript. BiomX Inc. (AMEX:PHGE) Q3 2025 Earnings Call Transcript November 12 2025 BiomX Inc. beats earnings expectations. Reported EPS is $0 expectations were $-0.32. Operator: Good morning and welcome to BiomX Third Quarter 2025 Financial Results and Program Update Conference Call. [Operator Instructions] As a reminder this conference call is being recorded. I would now like [….]
Thu Nov 13, 2025
BiomX Announces Positive FDA Feedback Supporting Next-Generation Phage Cocktail Program for Diabetic Foot Infections. New FDA feedback confirms clinical pathway for fixed multi-phage cocktail BX011 expanding development into diabetic foot infections (DFI) and unlocking a major commercial opportunity
Tue Nov 4, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
PHGE Stock trends
PHGE Stock performance
PHGE Stock analysis
PHGE investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.